Pharmacokinetics of Midazolam and Metabolites in a Patient With Refractory Status Epilepticus Treated With Extraordinary Doses of Midazolam
Authors:
- Bettina LinkBLBettina Link
- Nathalie GrignaschiNGNathalie Grignaschi
- Oliver KummerOKOliver Kummer
- Stephan RueggSRStephan Ruegg
- Manuel HaschkeMHManuel Haschke
- Stephan KrähenbühlSKStephan Krähenbühl
- 1 February 2008
- journal article
- case report
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 30 (1) , 120-124
Abstract
The authors present a patient with refractory epilepsy who was treated with very high doses (up to 4 mg/min) of intravenous midazolam, phenytoin, carbamazepine, and other antiepileptics. Because it was known from the literature that the half-life of midazolam can increase at high dosage, the kinetics of midazolam (MDZ), 1'-hydroxymidazolam, and 4-hydroxymidazolam were assessed at steady state (dosage 1 mg/min) and after stopping treatment. Total body clearance of MDZ (33 L/kg) and intrinsic hepatic clearance (19 mL/min/kg) at steady state were both five to 10 times higher than after normal therapeutic doses, demonstrating hepatic cytochrome (CYP) 3A induction. Despite the high body clearance, the half-life of MDZ was in the range of 24 hours, approximately 10 times higher than after normal therapeutic doses. The volume of distribution at steady state was 33 L/kg, approximately 50 times higher than after normal therapeutic doses. The free fraction of MDZ was 58% at steady state, much higher than the 3% to 6% at normal therapeutic doses. The kinetics of intravenous MDZ is strongly dependent on its dose and on hepatic CYP3A activity. Even in patients with hepatic CYP3A induction, the half-life of MDZ increases with high doses as a result of a rise in its volume of distribution, which is a consequence of an increase in the free fraction of MDZ.Keywords
This publication has 21 references indexed in Scilit:
- In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolamClinical Pharmacology & Therapeutics, 2004
- The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activityClinical Pharmacology & Therapeutics, 2003
- Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotypingClinical Pharmacology & Therapeutics, 2002
- Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: Effect of ketoconazoleClinical Pharmacology & Therapeutics, 1999
- Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism*Clinical Pharmacology & Therapeutics, 1996
- Interaction between grapefruit juice and midazolam in humans*Clinical Pharmacology & Therapeutics, 1995
- Pharmacokinetics of midazolam administered by continuous intravenous infusion to intensive care patientsCritical Care Medicine, 1992
- Decreased plasma albumin concentration results in increased volume of distribution and decreased elimination of midazolam in intensive care patientsClinical Pharmacology & Therapeutics, 1989
- Clinical Pharmacokinetics of Long-Term Infusion of Midazolam in Critically Ill Patients — Preliminary ResultsAnaesthesia and Intensive Care, 1987
- Physiologie and temporal variation in hepatic elimination of midazolamClinical Pharmacology & Therapeutics, 1982